APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Immune Mediated Tumor Killing Assays Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Immune Mediated Tumor Killing Assays Service Market Analysis and Forecast 2026-2032

Report ID 17443825033 July 2026181 pages

Choose your research edition.

Industry ResearchImmune Mediated Tumor Killing Assays Service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Mediated Tumor Killing Assays Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Immune Mediated Tumor Killing Assays Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Mediated Tumor Killing Assays Service Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Mediated Tumor Killing Assays Service Market Analysis and Forecast 2026-2032181 pages · $4,950 USD

Market perspective

The global Immune Mediated Tumor Killing Assays Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Immune Mediated Tumor Killing Assays Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Immune Mediated Tumor Killing Assays Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Immune Mediated Tumor Killing Assays Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Immune Mediated Tumor Killing Assays Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Immune Mediated Tumor Killing Assays Service include Agilent, Laboratories, Explicyte, Reaction Biology, Axion BioSystems, Sartorius, ICE Bioscience, Shanghai Saily Biotechnology and ProBio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Immune Mediated Tumor Killing Assays Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immune Mediated Tumor Killing Assays Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Immune Mediated Tumor Killing Assays Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immune Mediated Tumor Killing Assays Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immune Mediated Tumor Killing Assays Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Immune Mediated Tumor Killing Assays Service revenue, projected growth trends, production technology, application and end-user industry.

Immune Mediated Tumor Killing Assays Service Segment by Company

Agilent

Laboratories

Explicyte

Reaction Biology

Axion BioSystems

Sartorius

ICE Bioscience

Shanghai Saily Biotechnology

ProBio

Charles River

Imodels

Xeno Diagnostics

Cyagen

MarinBio

Pharmalegacy

Celentyx

Crown Bioscience

Cellomatics Biosciences

Immune Mediated Tumor Killing Assays Service Segment by Type

Cytotoxic T Cell Assay

Natural Killer (NK) Cell Assay

Other

Immune Mediated Tumor Killing Assays Service Segment by Application

Cancer Research

Infectious Disease Research

Immunotherapy Development

Immune Mediated Tumor Killing Assays Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Mediated Tumor Killing Assays Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Mediated Tumor Killing Assays Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Mediated Tumor Killing Assays Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Immune Mediated Tumor Killing Assays Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Immune Mediated Tumor Killing Assays Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immune Mediated Tumor Killing Assays Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cytotoxic T Cell Assay Major Player Table 3. Natural Killer (NK) Cell Assay Major Player Table 4. Other Major Player Table 5. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Research Major Player Table 7. Infectious Disease Research Major Player Table 8. Immunotherapy Development Major Player Table 9. Immune Mediated Tumor Killing Assays Service Industry Trends Table 10. Immune Mediated Tumor Killing Assays Service Industry Drivers Table 11. Immune Mediated Tumor Killing Assays Service Industry Opportunities and Challenges Table 12. Immune Mediated Tumor Killing Assays Service Industry Restraints Table 13. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Immune Mediated Tumor Killing Assays Service Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Immune Mediated Tumor Killing Assays Service Market Share by Region (2021-2026) Table 16. Global Immune Mediated Tumor Killing Assays Service Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Immune Mediated Tumor Killing Assays Service Market Share by Region (2027-2032) Table 18. Global Immune Mediated Tumor Killing Assays Service Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Players (2021-2026) Table 20. Global Immune Mediated Tumor Killing Assays Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Immune Mediated Tumor Killing Assays Service Key Players Headquarters & Area Served Table 22. Global Immune Mediated Tumor Killing Assays Service Players, Product Type & Application Table 23. Global Immune Mediated Tumor Killing Assays Service Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Immune Mediated Tumor Killing Assays Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Immune Mediated Tumor Killing Assays Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Type (2021-2026) Table 30. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Type (2027-2032) Table 31. Global Immune Mediated Tumor Killing Assays Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Application (2021-2026) Table 35. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Application (2027-2032) Table 36. Agilent Company Information Table 37. Agilent Business Overview Table 38. Agilent Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Agilent Immune Mediated Tumor Killing Assays Service Product Portfolio Table 40. Agilent Recent Development Table 41. Laboratories Company Information Table 42. Laboratories Business Overview Table 43. Laboratories Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Laboratories Immune Mediated Tumor Killing Assays Service Product Portfolio Table 45. Laboratories Recent Development Table 46. Explicyte Company Information Table 47. Explicyte Business Overview Table 48. Explicyte Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Explicyte Immune Mediated Tumor Killing Assays Service Product Portfolio Table 50. Explicyte Recent Development Table 51. Reaction Biology Company Information Table 52. Reaction Biology Business Overview Table 53. Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Reaction Biology Immune Mediated Tumor Killing Assays Service Product Portfolio Table 55. Reaction Biology Recent Development Table 56. Axion BioSystems Company Information Table 57. Axion BioSystems Business Overview Table 58. Axion BioSystems Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Axion BioSystems Immune Mediated Tumor Killing Assays Service Product Portfolio Table 60. Axion BioSystems Recent Development Table 61. Sartorius Company Information Table 62. Sartorius Business Overview Table 63. Sartorius Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Sartorius Immune Mediated Tumor Killing Assays Service Product Portfolio Table 65. Sartorius Recent Development Table 66. ICE Bioscience Company Information Table 67. ICE Bioscience Business Overview Table 68. ICE Bioscience Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. ICE Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio Table 70. ICE Bioscience Recent Development Table 71. Shanghai Saily Biotechnology Company Information Table 72. Shanghai Saily Biotechnology Business Overview Table 73. Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product Portfolio Table 75. Shanghai Saily Biotechnology Recent Development Table 76. ProBio Company Information Table 77. ProBio Business Overview Table 78. ProBio Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. ProBio Immune Mediated Tumor Killing Assays Service Product Portfolio Table 80. ProBio Recent Development Table 81. Charles River Company Information Table 82. Charles River Business Overview Table 83. Charles River Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Charles River Immune Mediated Tumor Killing Assays Service Product Portfolio Table 85. Charles River Recent Development Table 86. Imodels Company Information Table 87. Imodels Business Overview Table 88. Imodels Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Imodels Immune Mediated Tumor Killing Assays Service Product Portfolio Table 90. Imodels Recent Development Table 91. Xeno Diagnostics Company Information Table 92. Xeno Diagnostics Business Overview Table 93. Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product Portfolio Table 95. Xeno Diagnostics Recent Development Table 96. Cyagen Company Information Table 97. Cyagen Business Overview Table 98. Cyagen Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Cyagen Immune Mediated Tumor Killing Assays Service Product Portfolio Table 100. Cyagen Recent Development Table 101. MarinBio Company Information Table 102. MarinBio Business Overview Table 103. MarinBio Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. MarinBio Immune Mediated Tumor Killing Assays Service Product Portfolio Table 105. MarinBio Recent Development Table 106. Pharmalegacy Company Information Table 107. Pharmalegacy Business Overview Table 108. Pharmalegacy Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Pharmalegacy Immune Mediated Tumor Killing Assays Service Product Portfolio Table 110. Pharmalegacy Recent Development Table 111. Celentyx Company Information Table 112. Celentyx Business Overview Table 113. Celentyx Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Celentyx Immune Mediated Tumor Killing Assays Service Product Portfolio Table 115. Celentyx Recent Development Table 116. Crown Bioscience Company Information Table 117. Crown Bioscience Business Overview Table 118. Crown Bioscience Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Crown Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio Table 120. Crown Bioscience Recent Development Table 121. Cellomatics Biosciences Company Information Table 122. Cellomatics Biosciences Business Overview Table 123. Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product Portfolio Table 125. Cellomatics Biosciences Recent Development Table 126. North America Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026) & (US$ Million) Table 127. North America Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032) & (US$ Million) Table 128. North America Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. North America Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026) & (US$ Million) Table 132. North America Immune Mediated Tumor Killing Assays Service Revenue by Country (US$ Million) & (2027-2032) Table 133. Europe Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026) & (US$ Million) Table 134. Europe Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032) & (US$ Million) Table 135. Europe Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026) & (US$ Million) Table 139. Europe Immune Mediated Tumor Killing Assays Service Revenue by Country (US$ Million) & (2027-2032) Table 140. China Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026) & (US$ Million) Table 141. China Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032) & (US$ Million) Table 142. China Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026) & (US$ Million) Table 143. China Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026) & (US$ Million) Table 145. Asia Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032) & (US$ Million) Table 146. Asia Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026) & (US$ Million) Table 147. Asia Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032) & (US$ Million) Table 148. Asia Immune Mediated Tumor Killing Assays Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Asia Immune Mediated Tumor Killing Assays Service Revenue by Region (US$ Million) & (2021-2026) Table 150. Asia Immune Mediated Tumor Killing Assays Service Revenue by Region (US$ Million) & (2027-2032) Table 151. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026) & (US$ Million) Table 152. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032) & (US$ Million) Table 153. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026) & (US$ Million) Table 154. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032) & (US$ Million) Table 155. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026) & (US$ Million) Table 157. SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country (US$ Million) & (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Immune Mediated Tumor Killing Assays Service Image Figure 2. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Mediated Tumor Killing Assays Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cytotoxic T Cell Assay Image Figure 5. Natural Killer (NK) Cell Assay Image Figure 6. Other Image Figure 7. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Immune Mediated Tumor Killing Assays Service Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Research Image Figure 10. Infectious Disease Research Image Figure 11. Immunotherapy Development Image Figure 12. Global Immune Mediated Tumor Killing Assays Service Market Size (US$ Million) & (2021-2032) Figure 13. Global Immune Mediated Tumor Killing Assays Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Immune Mediated Tumor Killing Assays Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Immune Mediated Tumor Killing Assays Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Immune Mediated Tumor Killing Assays Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Type (2021-2032) Figure 20. Global Immune Mediated Tumor Killing Assays Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Application (2021-2032) Figure 23. North America Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032) Figure 25. North America Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032) Figure 26. North America Immune Mediated Tumor Killing Assays Service Revenue Share by Country (2021-2032) Figure 27. United States Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032) Figure 32. Europe Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032) Figure 33. Europe Immune Mediated Tumor Killing Assays Service Revenue Share by Country (2021-2032) Figure 34. Germany Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032) Figure 44. China Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032) Figure 45. Asia Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032) Figure 47. Asia Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032) Figure 48. Asia Immune Mediated Tumor Killing Assays Service Revenue Share by Region (2021-2032) Figure 49. Japan Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032) Figure 57. SAMEA Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032) Figure 58. SAMEA Immune Mediated Tumor Killing Assays Service Revenue Share by Country (2021-2032) Figure 59. Brazil Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Immune Mediated Tumor Killing Assays Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cytotoxic T Cell Assay
  • Natural Killer (NK) Cell Assay
  • Other
Applications
  • Cancer Research
  • Infectious Disease Research
  • Immunotherapy Development
Companies covered
  • Agilent
  • Laboratories
  • Explicyte
  • Reaction Biology
  • Axion BioSystems
  • Sartorius
  • ICE Bioscience
  • Shanghai Saily Biotechnology
  • ProBio
  • Charles River
  • Imodels
  • Xeno Diagnostics
  • Cyagen
  • MarinBio
  • Pharmalegacy
  • Celentyx
  • Crown Bioscience
  • Cellomatics Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immune Mediated Tumor Killing Assays Service Market by Type
  3. 1.2.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cytotoxic T Cell Assay
  5. 1.2.3 Natural Killer (NK) Cell Assay
  6. 1.2.4 Other
  7. 1.3 Immune Mediated Tumor Killing Assays Service Market by Application
  8. 1.3.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer Research
  10. 1.3.3 Infectious Disease Research
  11. 1.3.4 Immunotherapy Development
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Immune Mediated Tumor Killing Assays Service Market Dynamics
  1. 2.1 Immune Mediated Tumor Killing Assays Service Industry Trends
  2. 2.2 Immune Mediated Tumor Killing Assays Service Industry Drivers
  3. 2.3 Immune Mediated Tumor Killing Assays Service Industry Opportunities and Challenges
  4. 2.4 Immune Mediated Tumor Killing Assays Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Immune Mediated Tumor Killing Assays Service Market Perspective (2021-2032)
  2. 3.2 Global Immune Mediated Tumor Killing Assays Service Growth Trends by Region
  3. 3.2.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immune Mediated Tumor Killing Assays Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Immune Mediated Tumor Killing Assays Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Immune Mediated Tumor Killing Assays Service Revenue by Players
  2. 4.1.1 Global Immune Mediated Tumor Killing Assays Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Immune Mediated Tumor Killing Assays Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immune Mediated Tumor Killing Assays Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Immune Mediated Tumor Killing Assays Service Key Players Headquarters & Area Served
  7. 4.4 Global Immune Mediated Tumor Killing Assays Service Players, Product Type & Application
  8. 4.5 Global Immune Mediated Tumor Killing Assays Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Immune Mediated Tumor Killing Assays Service Market CR5 and HHI
  11. 4.6.3 2025 Immune Mediated Tumor Killing Assays Service Tier 1, Tier 2, and Tier 3
5 Immune Mediated Tumor Killing Assays Service Market Size by Type
  1. 5.1 Global Immune Mediated Tumor Killing Assays Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2032)
  3. 5.3 Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Type (2021-2032)
6 Immune Mediated Tumor Killing Assays Service Market Size by Application
  1. 6.1 Global Immune Mediated Tumor Killing Assays Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2032)
  3. 6.3 Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Agilent
  2. 7.1.1 Agilent Company Information
  3. 7.1.2 Agilent Business Overview
  4. 7.1.3 Agilent Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Agilent Immune Mediated Tumor Killing Assays Service Product Portfolio
  6. 7.1.5 Agilent Recent Developments
  7. 7.2 Laboratories
  8. 7.2.1 Laboratories Company Information
  9. 7.2.2 Laboratories Business Overview
  10. 7.2.3 Laboratories Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Laboratories Immune Mediated Tumor Killing Assays Service Product Portfolio
  12. 7.2.5 Laboratories Recent Developments
  13. 7.3 Explicyte
  14. 7.3.1 Explicyte Company Information
  15. 7.3.2 Explicyte Business Overview
  16. 7.3.3 Explicyte Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Explicyte Immune Mediated Tumor Killing Assays Service Product Portfolio
  18. 7.3.5 Explicyte Recent Developments
  19. 7.4 Reaction Biology
  20. 7.4.1 Reaction Biology Company Information
  21. 7.4.2 Reaction Biology Business Overview
  22. 7.4.3 Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Reaction Biology Immune Mediated Tumor Killing Assays Service Product Portfolio
  24. 7.4.5 Reaction Biology Recent Developments
  25. 7.5 Axion BioSystems
  26. 7.5.1 Axion BioSystems Company Information
  27. 7.5.2 Axion BioSystems Business Overview
  28. 7.5.3 Axion BioSystems Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Axion BioSystems Immune Mediated Tumor Killing Assays Service Product Portfolio
  30. 7.5.5 Axion BioSystems Recent Developments
  31. 7.6 Sartorius
  32. 7.6.1 Sartorius Company Information
  33. 7.6.2 Sartorius Business Overview
  34. 7.6.3 Sartorius Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sartorius Immune Mediated Tumor Killing Assays Service Product Portfolio
  36. 7.6.5 Sartorius Recent Developments
  37. 7.7 ICE Bioscience
  38. 7.7.1 ICE Bioscience Company Information
  39. 7.7.2 ICE Bioscience Business Overview
  40. 7.7.3 ICE Bioscience Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 ICE Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio
  42. 7.7.5 ICE Bioscience Recent Developments
  43. 7.8 Shanghai Saily Biotechnology
  44. 7.8.1 Shanghai Saily Biotechnology Company Information
  45. 7.8.2 Shanghai Saily Biotechnology Business Overview
  46. 7.8.3 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product Portfolio
  48. 7.8.5 Shanghai Saily Biotechnology Recent Developments
  49. 7.9 ProBio
  50. 7.9.1 ProBio Company Information
  51. 7.9.2 ProBio Business Overview
  52. 7.9.3 ProBio Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ProBio Immune Mediated Tumor Killing Assays Service Product Portfolio
  54. 7.9.5 ProBio Recent Developments
  55. 7.10 Charles River
  56. 7.10.1 Charles River Company Information
  57. 7.10.2 Charles River Business Overview
  58. 7.10.3 Charles River Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Charles River Immune Mediated Tumor Killing Assays Service Product Portfolio
  60. 7.10.5 Charles River Recent Developments
  61. 7.11 Imodels
  62. 7.11.1 Imodels Company Information
  63. 7.11.2 Imodels Business Overview
  64. 7.11.3 Imodels Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Imodels Immune Mediated Tumor Killing Assays Service Product Portfolio
  66. 7.11.5 Imodels Recent Developments
  67. 7.12 Xeno Diagnostics
  68. 7.12.1 Xeno Diagnostics Company Information
  69. 7.12.2 Xeno Diagnostics Business Overview
  70. 7.12.3 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product Portfolio
  72. 7.12.5 Xeno Diagnostics Recent Developments
  73. 7.13 Cyagen
  74. 7.13.1 Cyagen Company Information
  75. 7.13.2 Cyagen Business Overview
  76. 7.13.3 Cyagen Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cyagen Immune Mediated Tumor Killing Assays Service Product Portfolio
  78. 7.13.5 Cyagen Recent Developments
  79. 7.14 MarinBio
  80. 7.14.1 MarinBio Company Information
  81. 7.14.2 MarinBio Business Overview
  82. 7.14.3 MarinBio Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 MarinBio Immune Mediated Tumor Killing Assays Service Product Portfolio
  84. 7.14.5 MarinBio Recent Developments
  85. 7.15 Pharmalegacy
  86. 7.15.1 Pharmalegacy Company Information
  87. 7.15.2 Pharmalegacy Business Overview
  88. 7.15.3 Pharmalegacy Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Pharmalegacy Immune Mediated Tumor Killing Assays Service Product Portfolio
  90. 7.15.5 Pharmalegacy Recent Developments
  91. 7.16 Celentyx
  92. 7.16.1 Celentyx Company Information
  93. 7.16.2 Celentyx Business Overview
  94. 7.16.3 Celentyx Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Celentyx Immune Mediated Tumor Killing Assays Service Product Portfolio
  96. 7.16.5 Celentyx Recent Developments
  97. 7.17 Crown Bioscience
  98. 7.17.1 Crown Bioscience Company Information
  99. 7.17.2 Crown Bioscience Business Overview
  100. 7.17.3 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Crown Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio
  102. 7.17.5 Crown Bioscience Recent Developments
  103. 7.18 Cellomatics Biosciences
  104. 7.18.1 Cellomatics Biosciences Company Information
  105. 7.18.2 Cellomatics Biosciences Business Overview
  106. 7.18.3 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product Portfolio
  108. 7.18.5 Cellomatics Biosciences Recent Developments
8 North America
  1. 8.1 North America Immune Mediated Tumor Killing Assays Service Revenue (2021-2032)
  2. 8.2 North America Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032)
  5. 8.3 North America Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032)
  9. 8.5 North America Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Immune Mediated Tumor Killing Assays Service Revenue by Country
  11. 8.6.1 North America Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Immune Mediated Tumor Killing Assays Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Immune Mediated Tumor Killing Assays Service Revenue (2021-2032)
  2. 9.2 Europe Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032)
  5. 9.3 Europe Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032)
  9. 9.5 Europe Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Immune Mediated Tumor Killing Assays Service Revenue by Country
  11. 9.6.1 Europe Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Immune Mediated Tumor Killing Assays Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Immune Mediated Tumor Killing Assays Service Revenue (2021-2032)
  2. 10.2 China Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2032)
  3. 10.2.1 China Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026)
  4. 10.2.2 China Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032)
  5. 10.3 China Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032)
  6. 10.4 China Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2032)
  7. 10.4.1 China Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026)
  8. 10.4.2 China Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032)
  9. 10.5 China Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immune Mediated Tumor Killing Assays Service Revenue (2021-2032)
  2. 11.2 Asia Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032)
  5. 11.3 Asia Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032)
  9. 11.5 Asia Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Immune Mediated Tumor Killing Assays Service Revenue by Country
  11. 11.6.1 Asia Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Immune Mediated Tumor Killing Assays Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immune Mediated Tumor Killing Assays Service Revenue (2021-2032)
  2. 12.2 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Immune Mediated Tumor Killing Assays Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Immune Mediated Tumor Killing Assays Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country
  11. 12.6.1 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Immune Mediated Tumor Killing Assays Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst